Aligos Therapeutics (ALGS) Stock Forecast & Price Target

$13.75

-0.73 (-5.04%)

(As of 08/21/2024 ET)

Aligos Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 1 Analyst Ratings

Based on 1 Wall Street analysts who have issued ratings for Aligos Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for ALGS.

Consensus Price Target

$75.00
445.45% Upside

High Forecast	$75.00
Average Forecast	$75.00
Low Forecast	$75.00

According to the 1 analysts' twelve-month price targets for Aligos Therapeutics, the average price target is $75.00. The highest price target for ALGS is $75.00, while the lowest price target for ALGS is $75.00. The average price target represents a forecasted upside of 445.45% from the current price of $13.75.

Type	Current Forecast 8/23/23 to 8/22/24	1 Month Ago 7/24/23 to 7/23/24	3 Months Ago 5/25/23 to 5/24/24	1 Year Ago 8/23/22 to 8/23/23
Consensus Rating	Buy	N/A	N/A	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	N/A	N/A	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	N/A	N/A	2 Buy rating(s)
Hold	0 Hold rating(s)	N/A	N/A	1 Hold rating(s)
Sell	0 Sell rating(s)	N/A	N/A	0 Sell rating(s)
Consensus Price Target	$75.00	N/A	N/A	$100.00
Forecasted Upside	445.45% Upside	N/A	N/A	255.56% Upside

Get Aligos Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter.

Ad Angel Publishing

What Is the $7,882 Stimulus Payment 2024?

Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.

Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here.

ALGS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALGS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Aligos Therapeutics Stock vs. The Competition

Type	Aligos Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.75	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	445.45% Upside	5,591.79% Upside	8.74% Upside
News Sentiment Rating	Neutral News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/19/2024	HC Wainwright 2 of 5 stars	E. Arce Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$75.00	+14,182.72%
1/16/2023	Piper Sandler 2 of 5 stars		Boost Target		$75.00 ➝ $175.00	+326.83%
1/6/2023	Jefferies Financial Group 2 of 5 stars		Upgrade	Hold ➝ Buy	$62.50 ➝ $75.00	+203.03%
11/3/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Ruiz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform	$75.00 ➝ $50.00	+86.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:21 AM ET.

ALGS Forecast - Frequently Asked Questions

What is Aligos Therapeutics' forecast for 2024?: According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Aligos Therapeutics is $75.00, with a high forecast of $75.00 and a low forecast of $75.00.
Should I buy or sell Aligos Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aligos Therapeutics in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALGS shares.
Does Aligos Therapeutics's stock price have much upside?: According to analysts, Aligos Therapeutics's stock has a predicted upside of 14,182.99% based on their 12-month stock forecasts.
What analysts cover Aligos Therapeutics?: Aligos Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days.
Do Wall Street analysts like Aligos Therapeutics more than its competitors?: Analysts like Aligos Therapeutics more than other "medical" companies. The consensus rating for Aligos Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ALGS compares to other companies.